Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 129

1.

Determinants of return at work of breast cancer patients: results from the OPTISOINS01 French prospective study.

Arfi A, Baffert S, Soilly AL, Huchon C, Reyal F, Asselain B, Neffati S, Rouzier R, Héquet D.

BMJ Open. 2018 May 18;8(5):e020276. doi: 10.1136/bmjopen-2017-020276.

PMID:
29776920
2.

Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.

Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua MJM, Hall CS, Engebraaten O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran FA, Cappelletti MR, Ignatiadis M, Proudhon C, Wolf DM, Bauldry JB, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker SY, Weber K, Reyal F, Amara D, Karhade MG, Mathiesen RR, Tokiniwa H, Llombart-Cussac A, Meddis A, Blanche P, d'Hollander K, Cottu P, Park JW, Loibl S, Latouche A, Pierga JY, Pantel K.

J Natl Cancer Inst. 2018 Apr 12. doi: 10.1093/jnci/djy018. [Epub ahead of print]

PMID:
29659933
3.

Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers.

Marangoni E, Laurent C, Coussy F, El-Botty R, Château-Joubert S, Servely JL, de Plater L, Assayag F, Dahmani A, Montaudon E, Nemati F, Fleury J, Vacher S, Gentien D, Rapinat A, Foidart P, Sounni NE, Noel A, Vincent-Salomon A, Lae M, Decaudin D, Roman-Roman S, Bièche I, Piccart M, Reyal F.

Clin Cancer Res. 2018 Feb 20. doi: 10.1158/1078-0432.CCR-17-3490. [Epub ahead of print]

PMID:
29463559
4.

Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort.

Hamy AS, Belin L, Bonsang-Kitzis H, Paquet C, Pierga JY, Lerebours F, Cottu P, Rouzier R, Savignoni A, Lae M, Reyal F.

Br J Cancer. 2018 Mar 20;118(6):e14. doi: 10.1038/bjc.2018.4. Epub 2018 Feb 20.

5.

Lymphovascular invasion after neoadjuvant chemotherapy is strongly associated with poor prognosis in breast carcinoma.

Hamy AS, Lam GT, Laas E, Darrigues L, Balezeau T, Guerin J, Livartowski A, Sadacca B, Pierga JY, Vincent-Salomon A, Coussy F, Becette V, Bonsang-Kitzis H, Rouzier R, Feron JG, Benchimol G, Laé M, Reyal F.

Breast Cancer Res Treat. 2018 Jun;169(2):295-304. doi: 10.1007/s10549-017-4610-0. Epub 2018 Jan 27.

PMID:
29374852
6.

Sentinel lymph node biopsy validation for large tumors.

Houvenaeghel G, Quilichini O, Cohen M, Reyal F, Classe JM, Mazouni C, Giard S, Carrabin N, Charitansky H, Darai E, Hudry D, Azuar P, Villet R, Gimbergues P, Tunon-DE-Lara C, Lambaudie E.

Int J Surg. 2017 Dec;48:275-280. doi: 10.1016/j.ijsu.2017.10.077. Epub 2017 Nov 24.

PMID:
29175020
7.

New insight for pharmacogenomics studies from the transcriptional analysis of two large-scale cancer cell line panels.

Sadacca B, Hamy-Petit AS, Laurent C, Gestraud P, Bonsang-Kitzis H, Pinheiro A, Abecassis J, Neuvial P, Reyal F.

Sci Rep. 2017 Nov 9;7(1):15126. doi: 10.1038/s41598-017-14770-6.

8.

Is post-mastectomy radiation therapy contributive in pN0-1mi breast cancer patients? Results of a French multi-centric cohort.

Forissier V, Tallet A, Cohen M, Classe JM, Reyal F, Chopin N, Mazouni C, Gimbergues P, Daraï E, Colombo PE, Azuar P, Lambaudie E, Houvenaeghel G.

Eur J Cancer. 2017 Dec;87:47-57. doi: 10.1016/j.ejca.2017.10.004. Epub 2017 Nov 3.

PMID:
29107861
9.

Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer.

Hamy AS, Pierga JY, Sabaila A, Laas E, Bonsang-Kitzis H, Laurent C, Vincent-Salomon A, Cottu P, Lerebours F, Rouzier R, Lae M, Reyal F.

Ann Oncol. 2017 Sep 1;28(9):2233-2240. doi: 10.1093/annonc/mdx309.

PMID:
28911063
10.

Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study.

de Nonneville A, Gonçalves A, Zemmour C, Cohen M, Classe JM, Reyal F, Colombo PE, Jouve E, Giard S, Barranger E, Sabatier R, Bertucci F, Boher JM, Houvenaeghel G.

Eur J Cancer. 2017 Oct;84:34-43. doi: 10.1016/j.ejca.2017.06.043. Epub 2017 Aug 4.

PMID:
28780480
11.

[Internal quality control on HER2 status determination in breast cancers: Experience of a cancer center].

Ngo C, Laé M, Ratour J, Hamel F, Taris C, Caly M, Le Cunff A, Reyal F, Kirova Y, Pierga JY, Vincent-Salomon A.

Bull Cancer. 2017 Jul - Aug;104(7-8):608-617. doi: 10.1016/j.bulcan.2017.05.002. Epub 2017 Jun 7. French.

PMID:
28595742
12.

Therapeutic escalation - De-escalation: Data from 15.508 early breast cancer treated with upfront surgery and sentinel lymph node biopsy (SLNB).

Houvenaeghel G, Lambaudie E, Cohen M, Classe JM, Reyal F, Garbay JR, Giard S, Chopin N, Martinez A, Rouzier R, Daraï E, Colombo PE, Coutant C, Gimbergues P, Azuar P, Villet R, Tunon de Lara C, Barranger E, Sabiani L, Goncalves A.

Breast. 2017 Aug;34:24-33. doi: 10.1016/j.breast.2017.04.008. Epub 2017 May 3.

PMID:
28475932
13.

Preoperative clinical pathway of breast cancer patients: determinants of compliance with EUSOMA quality indicators.

Héquet D, Huchon C, Baffert S, Alran S, Reyal F, Nguyen T, Combes A, Trichot C, Alves K, Berseneff H, Rouzier R.

Br J Cancer. 2017 May 23;116(11):1394-1401. doi: 10.1038/bjc.2017.114. Epub 2017 Apr 25.

14.

Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status.

Giacchetti S, Hamy AS, Delaloge S, Brain E, Berger F, Sigal-Zafrani B, Mathieu MC, Bertheau P, Guinebretière JM, Saghatchian M, Lerebours F, Mazouni C, Tembo O, Espié M, Reyal F, Marty M, Asselain B, Pierga JY.

Eur J Cancer. 2017 Apr;75:323-332. doi: 10.1016/j.ejca.2017.01.008. Epub 2017 Mar 7.

PMID:
28279941
15.

Medico-economic impact of MSKCC non-sentinel node prediction nomogram for ER-positive HER2-negative breast cancers.

Bonsang-Kitzis H, Mouttet-Boizat D, Guillot E, Feron JG, Fourchotte V, Alran S, Pierga JY, Cottu P, Lerebours F, Stevens D, Vincent-Salomon A, Sigal-Zafrani B, Campana F, Rouzier R, Reyal F.

PLoS One. 2017 Feb 27;12(2):e0169962. doi: 10.1371/journal.pone.0169962. eCollection 2017.

16.

Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study.

de Nonneville A, Gonçalves A, Zemmour C, Classe JM, Cohen M, Lambaudie E, Reyal F, Scherer C, Muracciole X, Colombo PE, Giard S, Rouzier R, Villet R, Chopin N, Darai E, Garbay JR, Gimbergues P, Sabiani L, Coutant C, Sabatier R, Bertucci F, Boher JM, Houvenaeghel G.

Breast Cancer Res Treat. 2017 Apr;162(2):307-316. doi: 10.1007/s10549-017-4136-5. Epub 2017 Feb 2.

PMID:
28155054
17.

A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways.

Hamy AS, Bonsang-Kitzis H, Lae M, Moarii M, Sadacca B, Pinheiro A, Galliot M, Abecassis J, Laurent C, Reyal F.

PLoS One. 2016 Dec 22;11(12):e0167397. doi: 10.1371/journal.pone.0167397. eCollection 2016.

18.

Predictive factors of pathologic complete response of HER2-positive breast cancer after preoperative chemotherapy with trastuzumab: development of a specific predictor and study of its utilities using decision curve analysis.

Jankowski C, Guiu S, Cortet M, Charon-Barra C, Desmoulins I, Lorgis V, Arnould L, Fumoleau P, Coudert B, Rouzier R, Coutant C, Reyal F.

Breast Cancer Res Treat. 2017 Jan;161(1):73-81. doi: 10.1007/s10549-016-4040-4. Epub 2016 Nov 2.

PMID:
27807808
19.

Axillary lymph node micrometastases decrease triple-negative early breast cancer survival.

Houvenaeghel G, Sabatier R, Reyal F, Classe JM, Giard S, Charitansky H, Rouzier R, Faure C, Garbay JR, Daraï E, Hudry D, Gimbergues P, Villet R, Lambaudie E.

Br J Cancer. 2016 Oct 25;115(9):1024-1031. doi: 10.1038/bjc.2016.283. Epub 2016 Sep 29.

20.

Impact of completion axillary lymph node dissection in patients with breast cancer and isolated tumour cells or micrometastases in sentinel nodes.

Houvenaeghel G, Boher JM, Reyal F, Cohen M, Garbay JR, Classe JM, Rouzier R, Giard S, Faure C, Charitansky H, Tunon de Lara C, Daraï E, Hudry D, Azuar P, Gimbergues P, Villet R, Sfumato P, Lambaudie E.

Eur J Cancer. 2016 Nov;67:106-118. doi: 10.1016/j.ejca.2016.08.003. Epub 2016 Sep 16.

PMID:
27640137
21.

No evidence for TSLP pathway activity in human breast cancer.

Ghirelli C, Sadacca B, Reyal F, Zollinger R, Michea P, Sirven P, Pattarini L, Martínez-Cingolani C, Guillot-Delost M, Nicolas A, Scholer-Dahirel A, Soumelis V.

Oncoimmunology. 2016 May 9;5(8):e1178438. doi: 10.1080/2162402X.2016.1178438. eCollection 2016 Aug.

22.

Prognostic Impact of Time to Ipsilateral Breast Tumor Recurrence after Breast Conserving Surgery.

Gosset M, Hamy AS, Mallon P, Delomenie M, Mouttet D, Pierga JY, Lae M, Fourquet A, Rouzier R, Reyal F, Feron JG.

PLoS One. 2016 Aug 5;11(8):e0159888. doi: 10.1371/journal.pone.0159888. eCollection 2016.

23.

Breast cancer in young women: Pathologic features and molecular phenotype.

Sabiani L, Houvenaeghel G, Heinemann M, Reyal F, Classe JM, Cohen M, Garbay JR, Giard S, Charitansky H, Chopin N, Rouzier R, Daraï E, Coutant C, Azuar P, Gimbergues P, Villet R, Tunon de Lara C, Lambaudie E.

Breast. 2016 Oct;29:109-16. doi: 10.1016/j.breast.2016.07.007. Epub 2016 Jul 29.

PMID:
27479041
24.

Correction: Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.

Bonsang-Kitzis H, Chaltier L, Belin L, Savignoni A, Rouzier R, Hamy AS, Sablin MP, Lerebours F, Bidard FC, Cottu P, Sastre-Garau X, Laé M, Pierga JY, Reyal F.

PLoS One. 2016 Jul 7;11(7):e0159123. doi: 10.1371/journal.pone.0159123. eCollection 2016.

25.

Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers.

Hatem R, El Botty R, Chateau-Joubert S, Servely JL, Labiod D, de Plater L, Assayag F, Coussy F, Callens C, Vacher S, Reyal F, Cosulich S, Diéras V, Bièche I, Marangoni E.

Oncotarget. 2016 Jul 26;7(30):48206-48219. doi: 10.18632/oncotarget.10195.

26.

Whole-genome profiling helps to classify phyllodes tumours of the breast.

Laé M, La Rosa P, Mandel J, Reyal F, Hupé P, Terrier P, Couturier J.

J Clin Pathol. 2016 Dec;69(12):1081-1087. doi: 10.1136/jclinpath-2016-203684. Epub 2016 May 20.

PMID:
27207013
27.

Biological network-driven gene selection identifies a stromal immune module as a key determinant of triple-negative breast carcinoma prognosis.

Bonsang-Kitzis H, Sadacca B, Hamy-Petit AS, Moarii M, Pinheiro A, Laurent C, Reyal F.

Oncoimmunology. 2015 Jun 24;5(1):e1061176. eCollection 2016.

28.

Low Concordance between Gene Expression Signatures in ER Positive HER2 Negative Breast Carcinoma Could Impair Their Clinical Application.

Laas E, Mallon P, Duhoux FP, Hamidouche A, Rouzier R, Reyal F.

PLoS One. 2016 Feb 19;11(2):e0148957. doi: 10.1371/journal.pone.0148957. eCollection 2016.

29.

[Hormonotherapy for breast cancer prevention: What about women with genetic predisposition to breast cancer?].

Sénéchal C, Reyal F, Callet N, This P, Noguès C, Stoppa-Lyonnet D, Fourme E.

Bull Cancer. 2016 Mar;103(3):273-81. doi: 10.1016/j.bulcan.2016.01.001. Epub 2016 Feb 3. Review. French.

PMID:
26852151
30.

Estrogen-Receptor, Progesterone-Receptor and HER2 Status Determination in Invasive Breast Cancer. Concordance between Immuno-Histochemistry and MapQuant™ Microarray Based Assay.

Mouttet D, Laé M, Caly M, Gentien D, Carpentier S, Peyro-Saint-Paul H, Vincent-Salomon A, Rouzier R, Sigal-Zafrani B, Sastre-Garau X, Reyal F.

PLoS One. 2016 Feb 1;11(2):e0146474. doi: 10.1371/journal.pone.0146474. eCollection 2016.

31.

Regulation of miR-200c/141 expression by intergenic DNA-looping and transcriptional read-through.

Batista L, Bourachot B, Mateescu B, Reyal F, Mechta-Grigoriou F.

Nat Commun. 2016 Jan 4;7:8959. doi: 10.1038/ncomms9959.

32.

Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.

Bonsang-Kitzis H, Chaltier L, Belin L, Savignoni A, Rouzier R, Sablin MP, Lerebours F, Bidard FC, Cottu P, Sastre-Garau X, Laé M, Pierga JY, Reyal F.

PLoS One. 2015 Dec 18;10(12):e0144359. doi: 10.1371/journal.pone.0144359. eCollection 2015. Erratum in: PLoS One. 2016;11(7):e0159123.

33.

Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort.

Hamy-Petit AS, Belin L, Bonsang-Kitzis H, Paquet C, Pierga JY, Lerebours F, Cottu P, Rouzier R, Savignoni A, Lae M, Reyal F.

Br J Cancer. 2016 Jan 12;114(1):44-52. doi: 10.1038/bjc.2015.426. Epub 2015 Dec 10. Erratum in: Br J Cancer. 2018 Feb 20;:.

34.

Impaired PRC2 activity promotes transcriptional instability and favors breast tumorigenesis.

Wassef M, Rodilla V, Teissandier A, Zeitouni B, Gruel N, Sadacca B, Irondelle M, Charruel M, Ducos B, Michaud A, Caron M, Marangoni E, Chavrier P, Le Tourneau C, Kamal M, Pasmant E, Vidaud M, Servant N, Reyal F, Meseure D, Vincent-Salomon A, Fre S, Margueron R.

Genes Dev. 2015 Dec 15;29(24):2547-62. doi: 10.1101/gad.269522.115. Epub 2015 Dec 4.

35.

Changes in correlation between promoter methylation and gene expression in cancer.

Moarii M, Boeva V, Vert JP, Reyal F.

BMC Genomics. 2015 Oct 28;16:873. doi: 10.1186/s12864-015-1994-2.

36.

ARF6-JIP3/4 regulate endosomal tubules for MT1-MMP exocytosis in cancer invasion.

Marchesin V, Castro-Castro A, Lodillinsky C, Castagnino A, Cyrta J, Bonsang-Kitzis H, Fuhrmann L, Irondelle M, Infante E, Montagnac G, Reyal F, Vincent-Salomon A, Chavrier P.

J Cell Biol. 2015 Oct 26;211(2):339-58. doi: 10.1083/jcb.201506002.

37.

Integrative DNA methylation and gene expression analysis to assess the universality of the CpG island methylator phenotype.

Moarii M, Reyal F, Vert JP.

Hum Genomics. 2015 Oct 13;9:26. doi: 10.1186/s40246-015-0048-9.

38.

L'Epidermal Growth Factor Receptor (EGFR) est une cible thérapeutique pour un sous-groupe de tumeurs de vessie agressives de phénotype de type basal.

Neuzillet Y, Rebouissou S, De Reynies A, Lepage M, Krucker C, Chapeaublanc E, Herault A, Kamoun A, Caillault A, Letouze E, Elarouci N, Decoux Y, Molinie V, Vordos D, Laplanche A, Maille P, Soyeux P, Ofualuka K, Reyal F, Biton A, Sibony M, Paoletti X, Southgate J, Benhamou S, Allory Y, Radvanyi F, Lebret T.

Prog Urol. 2014 Nov;24(13):806. doi: 10.1016/j.purol.2014.08.053. Epub 2014 Oct 30. French. No abstract available.

PMID:
26461580
39.

Prognostic impact of discrepant Ki67 and mitotic index on hormone receptor-positive, HER2-negative breast carcinoma.

Rossi L, Laas E, Mallon P, Vincent-Salomon A, Guinebretiere JM, Lerebours F, Rouzier R, Pierga JY, Reyal F.

Br J Cancer. 2015 Sep 29;113(7):996-1002. doi: 10.1038/bjc.2015.239. Epub 2015 Sep 17.

40.

Impact of Adjuvant Chemotherapy on Breast Cancer Survival: A Real-World Population.

Rossi L, Stevens D, Pierga JY, Lerebours F, Reyal F, Robain M, Asselain B, Rouzier R.

PLoS One. 2015 Jul 27;10(7):e0132853. doi: 10.1371/journal.pone.0132853. eCollection 2015.

41.

Time-varying effect and long-term survival analysis in breast cancer patients treated with neoadjuvant chemotherapy.

Baulies S, Belin L, Mallon P, Senechal C, Pierga JY, Cottu P, Sablin MP, Sastre X, Asselain B, Rouzier R, Reyal F.

Br J Cancer. 2015 Jun 30;113(1):30-6. doi: 10.1038/bjc.2015.174. Epub 2015 Jun 16.

42.

Computing molecular signatures as optima of a bi-objective function: method and application to prediction in oncogenomics.

Gardeux V, Chelouah R, Wanderley MF, Siarry P, Braga AP, Reyal F, Rouzier R, Pusztai L, Natowicz R.

Cancer Inform. 2015 Apr 19;14:33-45. doi: 10.4137/CIN.S21111. eCollection 2015.

43.

Breast Cancer Cell-Derived GM-CSF Licenses Regulatory Th2 Induction by Plasmacytoid Predendritic Cells in Aggressive Disease Subtypes.

Ghirelli C, Reyal F, Jeanmougin M, Zollinger R, Sirven P, Michea P, Caux C, Bendriss-Vermare N, Donnadieu MH, Caly M, Fourchotte V, Vincent-Salomon A, Sigal-Zafrani B, Sastre-Garau X, Soumelis V.

Cancer Res. 2015 Jul 15;75(14):2775-87. doi: 10.1158/0008-5472.CAN-14-2386. Epub 2015 May 14.

44.

Response to dual HER2 blockade in a patient with HER3-mutant metastatic breast cancer.

Bidard FC, Ng CK, Cottu P, Piscuoglio S, Escalup L, Sakr RA, Reyal F, Mariani P, Lim R, Wang L, Norton L, Servois V, Sigal B, Vincent-Salomon A, Weigelt B, Pierga JY, Reis-Filho JS.

Ann Oncol. 2015 Aug;26(8):1704-9. doi: 10.1093/annonc/mdv217. Epub 2015 May 7.

PMID:
25953157
45.

Outcome of oncoplastic breast-conserving surgery following bracketing wire localization for large breast cancer.

Malhaire C, Hequet D, Falcou MC, Feron JG, Tardivon A, Leduey A, Guillot E, Mosseri V, Rouzier R, Couturaud B, Reyal F.

Breast. 2015 Aug;24(4):370-5. doi: 10.1016/j.breast.2015.02.037. Epub 2015 Apr 23.

PMID:
25913288
46.

p63/MT1-MMP axis is required for in situ to invasive transition in basal-like breast cancer.

Lodillinsky C, Infante E, Guichard A, Chaligné R, Fuhrmann L, Cyrta J, Irondelle M, Lagoutte E, Vacher S, Bonsang-Kitzis H, Glukhova M, Reyal F, Bièche I, Vincent-Salomon A, Chavrier P.

Oncogene. 2016 Jan 21;35(3):344-57. doi: 10.1038/onc.2015.87. Epub 2015 Apr 20.

PMID:
25893299
47.

Luminal progenitors restrict their lineage potential during mammary gland development.

Rodilla V, Dasti A, Huyghe M, Lafkas D, Laurent C, Reyal F, Fre S.

PLoS Biol. 2015 Feb 17;13(2):e1002069. doi: 10.1371/journal.pbio.1002069. eCollection 2015 Feb.

48.

Are we able to predict survival in ER-positive HER2-negative breast cancer? A comparison of web-based models.

Laas E, Mallon P, Delomenie M, Gardeux V, Pierga JY, Cottu P, Lerebours F, Stevens D, Rouzier R, Reyal F.

Br J Cancer. 2015 Mar 3;112(5):912-7. doi: 10.1038/bjc.2014.641. Epub 2015 Jan 15.

49.

The histone chaperone HJURP is a new independent prognostic marker for luminal A breast carcinoma.

Montes de Oca R, Gurard-Levin ZA, Berger F, Rehman H, Martel E, Corpet A, de Koning L, Vassias I, Wilson LO, Meseure D, Reyal F, Savignoni A, Asselain B, Sastre-Garau X, Almouzni G.

Mol Oncol. 2015 Mar;9(3):657-74. doi: 10.1016/j.molonc.2014.11.002. Epub 2014 Nov 20.

50.

Association of the number of sentinel lymph nodes harvested with survival in breast cancer.

Bonneau C, Bendifallah S, Reyal F, Rossi L, Rouzier R.

Eur J Surg Oncol. 2015 Jan;41(1):52-8. doi: 10.1016/j.ejso.2014.11.004. Epub 2014 Nov 17.

PMID:
25466979

Supplemental Content

Support Center